Gold keeps refering to DR-70 and has attempted to compare it to Recaf. No WAY !!! No WAY !!! No WAY !!!

China should be very excited about the arival of Recaf.

BioCurex is very pleased to report the results obtained using the RECAF ELISA test on 77 bladder, kidney, stomach, and other types of cancers in comparison to 93 normal donor samples. It also compared the results with the chemiluminescence format. The results evidence a sensitivity of 90% with 95% specificity. Sensitivity is the ability of a test to detect existing cancers (if all patients who have a cancer test positive = 100% sensitivity).

Specificity represents how well the test avoids false positives (no false positives = 100% specificity). The regression coefficient (r) between the RECAF-ELISA and the RECAF-chemiluminescence test was 0.92 (maximum = 1) and the diagnostic correspondence between both tests was 97.8%. The work was done in collaboration with the Blokhin Cancer Research Centre, Moscow, Russia, and BioCurex expects to present the results at an International cancer congress later this year.
http://www.medicalnewstoday.com/arti...

Dr-70 ELISA has a sensitivity of 67 and a Specificity of 68. I would say that this is equivelant to existing tests. Very poor.

http://www.fda.gov/cdrh/reviews/K072...